Sutro Biopharma, Inc.

STRO

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001382101

SEC filings (opens in a new tab)

No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Sutro Biopharma, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025 All holders in Q3 2025

13F holders of STRO: Q3 2025 compared with Q4 2025
Measure	Q3 2025	Of which not filed for Q4 2025	Q4 2025	Change
Holders	88	3	63	−22
SharesConverted for a 1-for-10 split	5.34M	3.10K	5.60M	+262.6K (+4.9%)
Value	$46.4M	$27.8K	$64.8M	+$18.5M (+39.9%)

3 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (11)

Institutions that held Sutro Biopharma, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to STRO in Q4 2025
Institution	Shares	Value	% of portfolio
Balyasny Asset Management LLC	230,049	$2.66M	0.00%
Opaleye Management Inc.	190,671	$2.21M	0.29%
Point72 Asset Management, L.P.	179,088	$2.07M	0.00%
Spruce Street Capital LP	75,594	$874.6K	0.29%
Acuta Capital Partners, LLC	67,451	$780.4K	0.53%
ADAR1 Capital Management, LLC	67,077	$776.1K	0.06%
Citadel Advisors LLC	32,085	$371.2K	0.00%
Jane Street Group, LLC	22,945	$265.5K	0.00%
State of Tennessee, Treasury Department	7,400	$110.6K	0.00%
Wells Fargo & Company	100	$1.16K	0.00%
Fortitude Family Office, LLC	56	$648	0.00%

Sold out (33)

Institutions that held Sutro Biopharma, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of STRO in Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Suvretta Capital Management, LLC	6,488,324	$5.63M
Jacobs Levy Equity Management, Inc	445,750	$387.1K
DAFNA Capital Management LLC	437,079	$379.6K
Dimensional Fund Advisors LP	197,516	$171.5K
LPL Financial LLC	142,883	$124.1K
Susquehanna International Group, LLP	103,592	$90.0K
Standard Life Aberdeen plc	69,389	$60.3K
Cerity Partners LLC	68,061	$59.1K
Qube Research & Technologies Ltd	65,226	$56.6K
Catalyst Funds Management Pty Ltd	63,776	$55.4K
JustInvest LLC	60,184	$52.3K
Ieq Capital, LLC	59,752	$51.9K
Vontobel Holding Ltd.	50,000	$43.4K
Bridgeway Capital Management, LLC	42,900	$37.3K
Prudential Financial Inc	35,500	$30.8K
Bluefin Capital Management, LLC	34,934	$30.3K
Tower Research Capital LLC (TRC)	24,017	$20.9K
XTX Topco Ltd	19,131	$16.6K
China Universal Asset Management Co., Ltd.	14,860	$12.9K
Ground Swell Capital, LLC	14,345	$12.5K
Quantinno Capital Management LP	11,139	$9.67K
Revolve Wealth Partners, LLC	11,002	$9.55K
Mirae Asset Global Investments Co., Ltd.	3,277	$2.85K
Barclays PLC	2,767	$2.40K
Rockefeller Capital Management L.P.	2,365	$2.05K
GF Fund Management Co. Ltd.	1,918	$1.67K
Rise Advisors, LLC	769	$668
Bare Financial Services, Inc	549	$477
Jones Financial Companies LLLP	250	$222
Advisory Services Network, LLC	147	$128
True Wealth Design, LLC	45	$40
IFP Advisors, Inc	21	$18
SBI Securities Co., Ltd.	2	$2

Not filed for Q4 2025 yet (3)

Institutions that held Sutro Biopharma, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding STRO in Q3 2025 that haven't filed for Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Point72 Asia (Singapore) Pte. Ltd.	31,026	$26.9K
Accredited Wealth Management, LLC	5	$869
Cubist Systematic Strategies, LLC	10	$9